Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
Aurélien Mattuizzi(Twitter (United States)), Estibaliz Lazaro(Centre National de la Recherche Scientifique), Patrick Blanco(Centre National de la Recherche Scientifique), Eoghann White(Centre National de la Recherche Scientifique), Marine Cargou(Hôpital Pellegrin), Claire Leibler(Centre National de la Recherche Scientifique), Marie‐Elise Truchetet(Centre National de la Recherche Scientifique), Cécile Bordes(Centre National de la Recherche Scientifique), Dorothée Duluc(Centre National de la Recherche Scientifique), Isabelle Douchet(Centre National de la Recherche Scientifique), Loı̈c Sentilhes(Université de Bordeaux), Christophe Richez(Boston University), Nathalie Dugot‐Senant(Mayo Clinic), Tiphaine Fargeix(Centre National de la Recherche Scientifique), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), P. Duffau(Centre National de la Recherche Scientifique), Jean‐François Viallard(Centre Hospitalier Universitaire de Bordeaux), Fanny Sauvestre(Centre National de la Recherche Scientifique)
Cited by 17
Related Papers
Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection
|JAMA Pediatrics|2021|1.4k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study
|American Journal of Obstetrics and Gynecology|2021|310